<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We retrospectively assessed whether heritable <z:hpo ids='HP_0100724'>thrombophilia</z:hpo>-hypofibrinolysis was more common in patients developing venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> after total hip replacement than among control patients who did not develop venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo>, as an approach to better identify causes of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> after total hip arthroplasty </plain></SENT>
<SENT sid="1" pm="."><plain>Twenty patients with proximal <z:hpo ids='HP_0002625'>deep venous thrombosis</z:hpo> after THA and 23 patients with symptomatic <z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> were compared with 43 control patients who did not have postoperative venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Five of 42 patients with venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (12%) and 0 of 43 control patients (0%) had <z:hpo ids='HP_0001976'>antithrombin III deficiency</z:hpo> (&lt; 75%) </plain></SENT>
<SENT sid="3" pm="."><plain>Nine of 42 patients with venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (21%) and 2 of 43 control patients (4.7%) had <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo> (&lt; 70%) </plain></SENT>
<SENT sid="4" pm="."><plain>Ten of 43 patients with venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> (9 heterozygous, 1 homozygous; 23%) and 1 of 43 control patients (heterozygous; 2%) had the prothrombin gene mutation </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who had venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> after total hip arthroplasty were more likely than matched control patients to have heritable <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> with antithrombin III or <z:hpo ids='HP_0005543'>protein C deficiency</z:hpo>, or homo-heterozygosity for the prothrombin gene mutation </plain></SENT>
<SENT sid="6" pm="."><plain>Screening for these three tests of heritable <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> before total hip arthroplasty should improve the identification of patients with a reduced risk of venous <z:hpo ids='HP_0001907'>thromboembolism</z:hpo> who may need only mild thromboprophylaxis, and of those patients with heritable <z:hpo ids='HP_0100724'>thrombophilia</z:hpo> in whom prophylaxis should be more aggressive </plain></SENT>
<SENT sid="7" pm="."><plain>LEVEL OF EVIDENCE: Prognostic study, Level II-1 (lesser-quality RCT) </plain></SENT>
<SENT sid="8" pm="."><plain>See the Guidelines for Authors for a complete description of levels of evidence </plain></SENT>
</text></document>